BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Raymond James 2020 Human Healthcare Innovation Conference on Thursday, June 18 at 10:20 a.m. Eastern Time. A live webcast and a copy of the presentation

- Real-world studies assessed persistence of BOTOX® (onabotulinumtoxinA) versus calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) - Multiple studies assessed long-term safety and sustained efficacy of BOTOX® in clinical practice - In addition to effectively treating migraine attacks when pain is moderate or severe, UBRELVY™ (ubrogepant) long-term trial data indicated that treating when pain is mild may significantly increase rates of pain freedom and absence

Immvira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announces the completion of Series B financing for 58 million US dollars.

Lifelong biotech leader Samuel Tong was a former executive in Asia of several large multinationals, including QIAGEN, Becton Dickinson and Abbott

MBio Diagnostics today announced delivery to the U.S. Department of Defense with funding for this effort provided by the Defense Health Program through the Joint Program Executive Office as part of a development program for a

Puzzle Medical Devices Inc., announces the closure of its first convertible debenture financing round led by Canadian entrepreneur Pascal Labrecque.

Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, announced the appointments of Julia Berretta, Ph.D, as Chief Executive Officer, and Mathieu Simon, M.D., as Chairman of the Board.

Oncopeptides AB announces that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, have been presented at the ongoing 25th European Hematology Association meeting, EHA.

Added responsibilities underscore company’s focus on commercial growth for the IRRAflow® and Hummingbird product lines

These Data Demonstrate Breadth of Takeda’s Portfolio and Pipeline with Three Hematology Presentations at the Virtual Summit